Table 1. Clinical trials in multiple myeloma and Waldenström’s macroglobulinemia patients with CAM as cancer treatment.
Disease | Targets | Drug combination (with selected references) |
---|---|---|
Breast cancer | Pro-inflammatory cytokines, monocytes … During and after surgery |
NSAIDs [18], aspirin [19], beta-blockers [20] |
NSCLC | Pro-inflammatory cytokines, monocytes … During and after surgery and/or radiotherapy |
NSAIDs [13, 14], aspirin [21], cimetidine [22], beta-blockers [14] |
NSCLC | Angiogenesis and endothelial cells | Metronomic [6, 23] or maintenance [1, 2] chemotherapy, aspirin [19, 24] |
All solid tumours, highly inflammatory (e.g. high neutrophils to lymphocytes Ratio) | Pro-inflammatory cytokines, monocytes, dendritic cells, T-cell trafficking … | NSAIDs [13], metronomic chemotherapy [23] |
Melanoma and other immunogenic tumours | Immune cells of the tumour environment (effector T-cells, Myeloid-derived suppressor cells, regulator T-cells, macrophages) | Immune checkpoint inhibitors [25], cellular immunotherapies [26] |